ASCO 2019

ASCO expert Robert Dreicer gives his quick take on why the enfortumab vedotin data reported at the meeting hold so much promise for advanced urothelial carcinoma patients who have progressed on prior therapy (1:25).

Investigator Daniel Petrylak summarizes the key results of the phase II EV-201 trial of the antibody–drug conjugate enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer (2:42).

Earle Burgess provides an independent commentary on the ENZAMET and TITAN results presented at the 2019 ASCO Annual Meeting, and discusses what these data mean for patients and physicians (2:57).

Christopher Sweeney presents the main findings of the ENZAMET trial, which evaluated the impact of supplementing androgen deprivation therapy with enzalutamide in men with advanced castration-sensitive prostate cancer (3:10).

Study author Axel Merseburger takes us through the TITAN trial investigating the addition of apalutamide to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting, and also addresses the key question of how physicians should choose between the available treatment options (3:03).

Biomarker analysis has given fresh insight into the response achieved with avelumab plus axitinib among advanced renal cell carcinoma patients participating in the JAVELIN Renal 101 trial.

Following treatment with the autologous cellular immunotherapy sipuleucel-T for metastatic castration-resistant prostate cancer, African–American men can expect to live longer than their Caucasian counterparts, indicates an analysis of the PROCEED registry.

Subgroup analysis of the IMmotion151 trial suggests improved survival with first-line atezolizumab plus bevacizumab versus sunitinib for locally advanced or metastatic renal cell carcinoma patients with sarcomatoid differentiation.

Brian Baumann presents their comparative analysis of the adverse event profiles of proton and photon radiotherapy in nonmetastatic patients receiving chemoradiotherapy with curative intent for various solid tumors, including lung cancer (5:28).

Mellisa Wheeler talks about how their mobile low dose-CT lung scanning unit – the Lung Bus – is helping to reach underserved populations in North Carolina, USA. She also comments on the issues of access to care and overscreening, and outlines the next steps (3:54).

ASCO expert David Graham tells us just why he thinks the 5-year survival data from the advanced non-small-cell lung cancer patients enrolled in the phase Ib KEYNOTE-001 trial are so remarkable (1:26).

Edward Garon presents the 5-year follow-up results of the advanced non-small-cell lung cancer cohort of the phase I KEYNOTE-001 trial of pembrolizumab monotherapy (4:12).

Advisory Board member Ross Camidge comments on his picks for the most exciting lung cancer research being presented at the 2019 ASCO Annual Meeting, including the RELAY trial and the ARROW trial of the RET inhibitor BLU-667 (3:13).

Supplementing the EGFR–tyrosine kinase inhibitor gefitinib with pemetrexed and carboplatin doubles progression-free survival in patients with advanced, chemotherapy-naïve non-small-cell lung cancer harboring activating EGFR mutations, according to phase III results.

Neoadjuvant immunotherapy produces encouraging major pathologic response rates among patients with resectable non-small-cell lung cancer, show data presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

Two studies presented at the 2019 ASCO Annual Meeting show a significant progression-free survival, but not overall survival, benefit with the addition of pemetrexed to bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer.